ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 219,14
0,38%
Dow Jones
39 494,41
0,27%
DAX
18 772,85
0,50%
Brent Oil
82,665
-1,53%
Bitcoin
60 707,26
-3,71%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. YS Biopharma Company Ltd (YS)

  7. YS Biopharma Company Ltd (YS) Actualités

YS YS Biopharma Company Ltd

0,942
-0,01 (-1,05%)
Dernière mise à jour : 20:32:03
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
YS Biopharma Company Ltd YS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,01 -1,05% 0,942 20:32:03
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,988 0,90 0,9976 0,952
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
07/5/202422:20PRNUSYS Biopharma to Hold Extraordinary General Meeting on May..
29/4/202414:00PRNUSYS Biopharma Receives Additional 180 Day Extension by Nasdaq..
19/4/202413:00PRNUSYS Biopharma Announces Unaudited Financial Results for the..
18/4/202414:00PRNUSYS Biopharma Granted Phase I Clinical Trial License of..
16/4/202414:00PRNUSYS Biopharma to Report First Nine Months of Fiscal Year 2024..
09/4/202414:00PRNUSYS Biopharma Announces Positive Interim Results of Pivotal..
03/4/202414:00PRNUSYS Biopharma Announces Full Repayment of US$40,000,000 Loan..
05/3/202414:00PRNUSYS Biopharma Announces Board Changes and Strategic..
22/2/202423:00PRNUSYS Biopharma Announces Results of Extraordinary General..
18/2/202410:30PRNUS/C O R R E C T I O N -- YS Biopharma Co., Ltd./
17/2/202402:20PRNUSYS Biopharma Announces Results of Extraordinary General..
14/2/202414:00PRNUSYS Biopharma to Hold an Extraordinary General Meeting on..
14/2/202413:50PRNUSYS Biopharma Announces Appointment of New Directors
12/2/202414:50PRNUSYS Biopharma Responds to a Notice of Extraordinary General..
09/2/202412:30PRNUSYS Biopharma Announces US$40 Million Private Placement..
09/2/202400:10PRNUSShareholders of YS Biopharma Announce an Extraordinary..
22/1/202423:00PRNUSYS Biopharma Announces Unaudited Financial Results for the..
08/1/202414:00PRNUSYS Biopharma Announces Changes to its Board Committees
20/12/202322:30PRNUSYS Biopharma Responds to Unauthorized Press Release..
20/12/202314:56PRNUSYS Biopharma Co., Ltd. to Hold Extraordinary General Meeting..
14/11/202314:30PRNUSNoble Capital Markets Initiates Coverage on YS Biopharma..
31/10/202313:30PRNUSYS Biopharma Announces Completion of Subject Enrollment in..
26/10/202314:30PRNUSYS Biopharma Announces Receipt of Nasdaq Notice
26/9/202314:30PRNUSYS Biopharma Announces First Subject Enrollment in Pivotal..
15/9/202314:30PRNUSYS Biopharma Granted Patent in the U.S. for Immunotherapy..
05/9/202314:30PRNUSYS Biopharma to Participate in Participate in Citi's 18th..
24/8/202322:15PRNUSYS Biopharma Announces Purchase of Shares by Company..
15/8/202323:00PRNUSYS Biopharma Announces Unaudited Financial Results for the..
26/7/202323:00PRNUSYS Biopharma Announces Financial Results for Fiscal Year..
21/7/202322:30PRNUSYS Biopharma to Report Financial Results for Fiscal Year..
01/6/202314:30PRNUSYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical..
18/5/202314:25PRNUSYS Biopharma to Participate in the Virtual Benchmark..
16/5/202313:00PRNUSYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical..

Dernières Valeurs Consultées

NASDAQ
YS
YS Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés